Total US pharma industry venture financing deals in Q4 2018 worth $3.5bn were announced, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

The value marked an increase of 6.5% over the previous quarter and a drop of 3.5% when compared with the last four-quarter average of $3.67bn.

The United States held a 74.3% share of the global pharma industry venture financing deal value that totalled $4.72bn in Q4 2018.

In terms of deal activity, the United States recorded 163 deals during Q4 2018, marking a rise of 29.4% over the previous quarter and a drop of 6.3% over the last four-quarter average.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

US pharma industry venture financing deals in Q4 2018: Top deals

The top five pharma industry venture financing deals accounted for 32.8% of the overall value during Q4 2018.

The combined value of the top five pharma industry venture financing deals stood at $1.15bn, against the overall value of $3.5bn recorded for the quarter. The top announced pharma industry venture financing deal tracked by GlobalData in Q4 2018 was Data Collective Venture Capital, DFJ Venture, The Goldman Sachs Group, Hanwha Asset Management, Innovation Endeavors, SoftBank Vision Fund, True Ventures and Two Sigma Ventures’ $400m venture financing of Zymergen.

In second place was the $400m venture financing of Relay Therapeutics by Alexandria Venture Investments, BVF Partners, Casdin Capital, D. E. Shaw Research, EcoR1 Capital, Foresite Capital Management, GV Management Co, Perceptive Advisors, SoftBank Vision Fund and Tavistock Group and in third place was Rakuten and SBI Holdings’ $134m venture financing of Rakuten Aspyrian.

The $120m venture financing of Mirum Pharmaceuticals by Deerfield Management, Frazier Healthcare Partners, New Enterprise Associates, Novo Holdings, Pappas Capital, RiverVest Venture Partners and Rock Springs Capital Management and Alexandria Venture Investments, ArrowMark Partners, Bay City Capital, Canaan Partners, Hillhouse Capital Group, Lilly Asia ventures, NS Investment Partners, Orbimed Advisors, Pfizer, Ping An Ventures, Quan Capital, Sofinnova Ventures, Surveyor Capital and Taiho Ventures’ venture financing of NextCure for $93m held fourth and fifth positions, respectively.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.